Researchers say if their results are confirmed through further study they are optimistic the approach could be used to treat chronic infections for the first time.

The trial was tailored to evaluate the therapy at multiple ascending dose levels, with three dose administrations per level.

Precision BioSciences, Inc. (NASDAQ:DTIL) revealed initial results from the first administration of PBGENE-HBV in cohort 1, ...

Precision BioSciences, Inc. (Nasdaq: DTIL), a clinical stage gene editing company utilizing its novel proprietary ARCUS® platform to develop in vivo g ...